Literature DB >> 21946786

Vision test variability in retinitis pigmentosa and psychosocial factors.

Ava K Bittner1, Mohamed A Ibrahim, Jennifer A Haythornthwaite, Marie Diener-West, Gislin Dagnelie.   

Abstract

PURPOSE: We explored whether greater amounts of short-term variability in visual acuity (VA), contrast sensitivity (CS), or visual field (VF) in retinitis pigmentosa (RP) was related to disease severity or psychosocial factors.
METHODS: We obtained spectral domain-optical coherence tomography in 27 RP subjects and determined variability (SD) of VA, CS, and VF during a mean of 16 tests self-administered at home on a personal computer twice a week. Subjects completed the Positive and Negative Affect Schedules at each personal computer-test session, and SF-36 general health and Beck Depression Inventory questionnaires on one occasion.
RESULTS: There was a 0.10 log unit increase in VA variability for every 0.58 logMAR increase (worse mean VA) (p = 0.001). For subjects with reduced foveal thickness, mean VA explained more of the total VA variability than foveal thickness (R² = 0.72 and 0.46, respectively, in simple linear regressions). There was a statistically significant 4.3% increased log VF area variability for every 50% mean log VF area decrease (p < 0.001); explaining most of the total variability in log VF area variability (R² = 0.44). When controlling for mean log VF area, there was a statistically significant increase in log VF area variability for subjects with greater than minimal depressive symptoms (p = 0.015), with increased mean irritability scores (p = 0.02), decreased SF-36 physical functioning subscale scores (p = 0.03), or decreased mean score for feeling active, strong, and proud (p = 0.008) (adjusted R² = 0.62). CS variability was low and not statistically significantly related to mean CS, macular thickness, or psychosocial factors.
CONCLUSIONS: Increased VA and VF variability was predicted largely by increased RP severity. Greater VF variability occurred in subjects with reduced VF who reported less physical activity or increased negative psychosocial states. These associations should be considered during clinical examinations and trials for RP.

Entities:  

Mesh:

Year:  2011        PMID: 21946786      PMCID: PMC3223543          DOI: 10.1097/OPX.0b013e3182348d0b

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  35 in total

1.  Mobility of people with retinitis pigmentosa as a function of vision and psychological variables.

Authors:  S Haymes; D Guest; A Heyes; A Johnston
Journal:  Optom Vis Sci       Date:  1996-10       Impact factor: 1.973

2.  Test-retest reliability of the multifocal electroretinogram and humphrey visual fields in patients with retinitis pigmentosa.

Authors:  William Seiple; Colleen J Clemens; Vivienne C Greenstein; Ronald E Carr; Karen Holopigian
Journal:  Doc Ophthalmol       Date:  2004-11       Impact factor: 2.379

3.  A global measure of perceived stress.

Authors:  S Cohen; T Kamarck; R Mermelstein
Journal:  J Health Soc Behav       Date:  1983-12

4.  Reproducibility of visual acuity measurements in patients with retinitis pigmentosa.

Authors:  S Grover; G A Fishman; L D Gilbert; R J Anderson
Journal:  Retina       Date:  1997       Impact factor: 4.256

5.  [Psycho-affective problems associated with retinitis pigmentosa].

Authors:  Z Strougo; A Badoux; D Duchanel
Journal:  J Fr Ophtalmol       Date:  1997       Impact factor: 0.818

6.  Reliability and consistency of visual acuity and contrast sensitivity measures in advanced eye disease.

Authors:  Ava K Kiser; Derek Mladenovich; Fariba Eshraghi; Debra Bourdeau; Gislin Dagnelie
Journal:  Optom Vis Sci       Date:  2005-11       Impact factor: 1.973

7.  Parent-administered visual acuity testing: is it reliable and can it improve office efficiency?

Authors:  Evelyn A Paysse; Larissa Camejo; Mohamed A W Hussein; David K Coats
Journal:  J AAPOS       Date:  2004-08       Impact factor: 1.220

8.  Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa.

Authors:  G A Fishman; L D Gilbert; R J Anderson; M F Marmor; R G Weleber; M A Viana
Journal:  Ophthalmology       Date:  1994-04       Impact factor: 12.079

9.  The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

Authors:  C A McHorney; J E Ware; A E Raczek
Journal:  Med Care       Date:  1993-03       Impact factor: 2.983

10.  A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol.

Authors:  Roy W Beck; Pamela S Moke; Andrew H Turpin; Frederick L Ferris; John Paul SanGiovanni; Chris A Johnson; Eileen E Birch; Danielle L Chandler; Terry A Cox; R Clifford Blair; Raymond T Kraker
Journal:  Am J Ophthalmol       Date:  2003-02       Impact factor: 5.258

View more
  25 in total

1.  Relationship between foveal cone structure and clinical measures of visual function in patients with inherited retinal degenerations.

Authors:  Kavitha Ratnam; Joseph Carroll; Travis C Porco; Jacque L Duncan; Austin Roorda
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-28       Impact factor: 4.799

2.  Applying theories and interventions from behavioral medicine to understand and reduce visual field variability in patients with vision loss.

Authors:  Collin Rozanski; Jennifer A Haythornthwaite; Gislin Dagnelie; Ava K Bittner
Journal:  Med Hypotheses       Date:  2014-05-09       Impact factor: 1.538

3.  Visual field changes following implantation of the Argus II retinal prosthesis.

Authors:  Stanislao Rizzo; Claudia Belting; Laura Cinelli; Luca Allegrini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-30       Impact factor: 3.117

4.  Patient-reported outcome measures in inherited retinal degeneration gene therapy trials.

Authors:  Gabrielle D Lacy; Maria Fernanda Abalem; David C Musch; Kanishka T Jayasundera
Journal:  Ophthalmic Genet       Date:  2020-02-26       Impact factor: 1.803

5.  Content generation for patient-reported outcome measures for retinal degeneration therapeutic trials.

Authors:  Gabrielle D Lacy; Maria Fernanda Abalem; Lilia T Popova; Erin P Santos; Gina Yu; Hanan Y Rakine; Julie M Rosenthal; Joshua R Ehrlich; David C Musch; K Thiran Jayasundera
Journal:  Ophthalmic Genet       Date:  2020-06-22       Impact factor: 1.803

6.  Harmonization of Outcomes and Vision Endpoints in Vision Restoration Trials: Recommendations from the International HOVER Taskforce.

Authors:  Lauren N Ayton; Joseph F Rizzo; Ian L Bailey; August Colenbrander; Gislin Dagnelie; Duane R Geruschat; Philip C Hessburg; Chris D McCarthy; Matthew A Petoe; Gary S Rubin; Philip R Troyk
Journal:  Transl Vis Sci Technol       Date:  2020-07-16       Impact factor: 3.283

7.  Intervisit variability of visual parameters in Leber congenital amaurosis caused by RPE65 mutations.

Authors:  Alejandro J Roman; Artur V Cideciyan; Sharon B Schwartz; Melani B Olivares; Elise Heon; Samuel G Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-15       Impact factor: 4.799

8.  Worse-than-usual visual fields measured in retinitis pigmentosa related to episodically decreased general health.

Authors:  Ava Katherine Bittner; Jennifer A Haythornthwaite; Marie Diener-West; Gislin Dagnelie
Journal:  Br J Ophthalmol       Date:  2012-12-04       Impact factor: 4.638

9.  Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy.

Authors:  Yi-Zhong Wang; Yu-Guang He; Gina Mitzel; Song Zhang; Mike Bartlett
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-13       Impact factor: 4.799

10.  Validation of electronic visual acuity (EVA) measurement against standardised ETDRS charts in patients with visual field loss from inherited retinal degenerations.

Authors:  Jasleen K Jolly; Kristin Juenemann; Heather Boagey; Marie Nadsady; Holly Bridge; Robert E Maclaren
Journal:  Br J Ophthalmol       Date:  2019-10-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.